Table 1.
Demographic and clinical characteristics of Covid-19 patients admitted to a treatment centre in the Arsi Zone, 2020–2021
| Demographic and clinical characteristics | Frequency (%) |
|---|---|
| Sex | |
| Female | 159 (40.0) |
| Male | 239 (60.0) |
| Age (mean = 41.5 (SD: 18.8) | |
| 0–24 years | 83 (20.9) |
| 25–34 | 102 (25.6) |
| 35–44 | 52 (13.1) |
| 45–54 | 46 (11.6) |
| 55 years and above | 115 (28.9) |
| Residence | |
| Rural | 156 (39.0) |
| Urban | 242 (61.0) |
| Health status on admission | |
| Asymptomatic | 95 (23.9) |
| Mild | 93 (23.4) |
| Moderate | 80 (20.0) |
| Severe | 130 (32.7) |
| Comorbidity | |
| Yes | 179 (45.0) |
| No | 219 (55.0) |
| Type of comorbidity | |
| Diabetes mellitus | 68 (17.1) |
| Hypertension | 41 (10.3) |
| Asthma | 33 (8.3) |
| Chronic pulmonary disease | 30 (7.5) |
| Chronic cardiac diseases | 23 (5.8) |
| Malignancy | 11 (2.8) |
| Chronic kidney disease | 7 (1.8) |
| HIV/AIDS | 6 (1.5) |
| Types of antibiotic administered | |
| Azithromycin only | 148 (37.2) |
| Azithromycin + ceftriaxone | 131 (32.9) |
| Azithromycin + vancomycin + ceftazidime | 50 (12.6) |
| Azithromycin + ceftriaxone + metronidazole | 30 (7.5) |
| Azithromycin + ceftriaxone + vancomycin | 24 (6.0) |
| Azithromycin + ceftriaxone + amoxicillin | 13 (3.3) |
| Azithromycin + ceftriaxone + ceftazidime | 2 (0.5) |
| Dexamethasone used | |
| Yes | 116 (29.1) |
| No | 282 (70.9) |
| Intranasal oxygen used | |
| Yes | 162 (59.3) |
| No | 236 (40.7) |
| Length of hospital stay (mean = 14.3 SD:4.8) | |
| 1–7 days | 12 (3.0) |
| 8–14 days | 248 (61.8) |
| 15–21 days | 113 (28.4) |
| 22–28 days | 13 (3.3) |
| More than 28 days | 14 (5.5) |